Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2015

Open Access 01-12-2015 | Review

Contact pathway of coagulation and inflammation

Author: Yi Wu

Published in: Thrombosis Journal | Issue 1/2015

Login to get access

Abstract

The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor high molecular weight kininogen (HK). This system has been investigated actively for more than 50 years. The components of this system and their interactions have been elucidated from in vitro experiments, which indicates that this system is prothrombotic by activating intrinsic pathway, and proinflammatory by producing bioactive peptide bradykinin. Although the activation of the contact system have been implicated in various types of human disease, in only a few instances is its role clearly defined. In the last 10 years, our understanding of the contact system, particularly its biology and (patho)physiology has greatly increased through investigations using gene-modified animal models. In this review we will describe a revitalized view of the contact system as a critical (patho)physiologic mediator of coagulation and inflammation.
Literature
1.
Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997;90(10):3819–43.PubMed
2.
Colman RW, Sartor RB, Adam AA, DeLa Cadena RA, Stadnicki A. The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin Rev Allergy Immunol. 1998;16(4):365–84.CrossRefPubMed
3.
Bryant JW, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem. 2009;7(3):234–50.CrossRefPubMed
4.
Yang A, Dai J, Xie Z, Colman RW, Wu Q, Birge RB, et al. High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis. J Immunol. 2014;192(9):4398–408. PMCID: 4134950.CrossRefPubMed
5.
Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost. 2011;37(4):375–81.CrossRefPubMed
6.
Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143–56. PMCID: 2796262.CrossRefPubMedCentralPubMed
7.
Azevedo C, Saiardi A. Functions of inorganic polyphosphates in eukaryotic cells: a coat of many colours. Biochem Soc Trans. 2014;42(1):98–102.CrossRefPubMed
8.
9.
10.
van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood. 2009;114(4):881–90.CrossRefPubMed
11.
Liu J, Gao B-B, Clermont AC, Blair P, Chilcote TJ, Sinha S, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011;17(2):206–10.CrossRefPubMedCentralPubMed
12.
Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett. 2001;500(1–2):36–40.CrossRefPubMed
13.
Saito A, Munakata H. Analysis of plasma proteins that bind to glycosaminoglycans. Biochim Biophys Acta Gen Subj. 2007;1770(2):241–6.CrossRef
14.
Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost. 2010;104(5):875–85.CrossRefPubMed
15.
Wu Y, Rizzo V, Liu Y, Sainz IM, Schmuckler NG, Colman RW. Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(9):1968–75.CrossRefPubMed
16.
Khan MM, Bradford HN, Isordia-Salas I, Liu Y, Wu Y, Espinola RG, et al. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler Thromb Vasc Biol. 2006;26(10):2260–6. PMCID: 2637648.CrossRefPubMedCentralPubMed
17.
Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol. 2005;175(5):3377–85.CrossRefPubMed
18.
Ben Nasr A, Olsén A, Sjöbring U, Müller-Esterl W, Björck L. Assembly of human contact phase proteins and release of bradykinin at the surface of curli-expressing Escherichia coli. Mol Microbiol. 1996;20(5):927–35.CrossRefPubMed
19.
Ben Nasr A, Herwald H, Sjobring U, Renne T, Muller-Esterl W, Bjorck L. Absorption of kininogen from human plasma by Streptococcus pyogenes is followed by the release of bradykinin. The Biochemical J. 1997;326(Pt 3):657–60. PMCID: 1218718.
20.
Gershom ES, Sutherland MR, Lollar P, Pryzdial ELG. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost. 2010;8(5):1037–43.PubMed
21.
Mitropoulos KA, Reeves BE, O’Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coagul Fibrinolysis. 1993;4(2):223–34.CrossRefPubMed
22.
von dem Borne PA, Cox LM, Bouma BN. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor. Blood Coagul Fibrinolysis. 2006;17(4):251–7.CrossRef
23.
Colman RW. Contributions of Mayme Williams to the elucidation of the multiple functions of plasma kininogens. Thromb Haemost. 1992;68(2):99–101.PubMed
24.
Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271–81. PMCID: 2213000.CrossRefPubMedCentralPubMed
25.
Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513–8. PMCID: 2118228.CrossRefPubMedCentralPubMed
26.
Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19):3981–9. PMCID: 2981546.CrossRefPubMedCentralPubMed
27.
Renne T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis. 2006;36(2):148–51.CrossRefPubMed
28.
Bird JE, Smith PL, Wang X, Schumacher WA, Barbera F, Revelli JP, et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait. Thromb Haemost. 2012;107(6):1141–50.CrossRefPubMed
29.
Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011;118(19):5302–11.CrossRefPubMed
30.
Merkulov S, Zhang WM, Komar AA, Schmaier AH, Barnes E, Zhou Y, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274–81. PMCID: 2214772.CrossRefPubMedCentralPubMed
31.
Langhauser F, Gob E, Kraft P, Geis C, Schmitt J, Brede M, et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood. 2012;120(19):4082–92. PMCID: 3543983.CrossRefPubMedCentralPubMed
32.
Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012;10(7):1355–62.CrossRef
33.
Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102–7.
34.
von Brühl M-L, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819–35.CrossRef
35.
Oehmcke S, Mörgelin M, Herwald H. Activation of the Human Contact System on Neutrophil Extracellular Traps. J Innate Immun. 2009;1(3):225–30.CrossRefPubMed
36.
Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009;206(11):2381–95.CrossRefPubMedCentralPubMed
37.
Xu Y, Cai TQ, Castriota G, Zhou Y, Hoos L, Jochnowitz N, et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost. 2014;111(4):694–704.CrossRefPubMed
38.
Levi M, Hack CE, de Boer JP, Brandjes DP, xFc, ller HR, et al. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 1991;88(4):1155–60.CrossRefPubMedCentralPubMed
39.
Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI Deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325(3):153–8.CrossRefPubMed
40.
Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Investig. 1998;101(1):10–4.CrossRefPubMedCentralPubMed
41.
Frick I-M, Björck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost. 2007;98(9):497–502.PubMed
42.
Scharfstein J, Andrade D, Svensjö E, Oliveira AC, Nascimento CR. The Kallikrein-Kinin-System in Experimental Chagas Disease: A Paradigm to Investigate the Impact of Inflammatory Edema on GPCR-mediated pathways of Host Cell Invasion by Trypanosoma cruzi. Frontiers Immunol. 2013;3:396.
43.
Frick IM, Åkesson P, Herwald H, Mörgelin M, Malmsten M, Nägler DK, et al. The contact system—a novel branch of innate immunity generating antibacterial peptides. EMBO J. 2006;25(23):5569-78.
44.
Imamura T, Potempa J, Pike RN, Travis J. Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis. Infect Immun. 1995;63(5):1999–2003. PMCID: 173256.PubMedCentralPubMed
45.
Scharfstein J, Andrade D, Svensjö E, Oliveira AC, Nascimento CR. The Kallikrein-Kinin-System in Experimental Chagas Disease: A Paradigm to Investigate the Impact of Inflammatory Edema on GPCR-mediated pathways of Host Cell Invasion by Trypanosoma cruzi. Frontiers Immunol. 2013;3:396.
46.
Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (cp-0127): results of a randomized, double-blind, placebo-controlled trial. JAMA. 1997;277(6):482–7.CrossRefPubMed
47.
Lima APCA, Almeida PC, Tersariol ILS, Schmitz V, Schmaier AH, Juliano L, et al. Heparan sulfate modulates kinin release by trypanosoma cruzi through the activity of cruzipain. J Biol Chem. 2002;277(8):5875–81.CrossRefPubMed
48.
Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS. Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. PLoS Pathog. 2013;9(7):e1003470. PMCID: 3715459.CrossRefPubMedCentralPubMed
49.
DeLa Cadena RA, Laskin KJ, Pixley RA, Sartor RB, Schwab JH, Back N, et al. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. Am J Physiol. 1991;260(2 Pt 1):G213–9.
50.
Sainz IM, Isordia-Salas I, Castaneda JL, Agelan A, Liu B, DeLa Cadena RA, et al. Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum. 2005;52(8):2549–52.CrossRefPubMed
51.
Dai J, Agelan A, Yang A, Zuluaga V, Sexton D, Colman RW, et al. Role of plasma kallikrein-kinin system activation in synovial recruitment of endothelial progenitor cells in experimental arthritis. Arthritis Rheum. 2012;64(11):3574–82. PMCID: 3477304.CrossRefPubMedCentralPubMed
52.
Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH, et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest. 2011;121(9):3517–27.PubMedCentralPubMed
53.
Xie Z, Dai J, Yang A, Wu Y. A role for bradykinin in the development of anti-collagen antibody-induced arthritis. Rheumatology (Oxford). 2014;53(7):1301–6. PMCID: 4065007.CrossRef
54.
Szekanecz Z, Besenyei T, Szentpétery Á, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3):299–306.CrossRefPubMed
55.
Thairu N, Kiriakidis S, Dawson P, Paleolog E. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis. 2011;14(3):223–34.CrossRefPubMed
56.
Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE. The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum. 2007;56(6):1817–26.CrossRefPubMed
57.
Ruger B, Giurea A, Wanivenhaus AH, Zehetgruber H, Hollemann D, Yanagida G, et al. Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 2004;50(7):2157–66.CrossRefPubMed
58.
Wu Y, Dai J, Schmuckler NG, Bakdash N, Yoder MC, Overall CM, et al. Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2. J Thromb Haemost. 2010;8(1):185–93.CrossRefPubMedCentralPubMed
59.
Dai J, Zhu X, Yoder MC, Wu Y, Colman RW. Cleaved high-molecular-weight kininogen accelerates the onset of endothelial progenitor cell senescence by induction of reactive oxygen species. Arterioscler Thromb Vasc Biol. 2011;31(4):883–9.CrossRefPubMedCentralPubMed
60.
Devani M, Cugno M, Vecchi M, Ferrero S, Di Berardino F, Avesani EC, et al. Kallikrein-kinin system activation in Crohn’s disease: differences in intestinal and systemic markers. Am J Gastroenterol. 2002;97(8):2026–32.CrossRefPubMed
61.
Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;289(2):G361-6.
62.
Stadnicki A, Sartor RB, Janardham R, Stadnicka I, Adam AA, Blais Jr C, et al. Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats. Gut. 1998;43(3):365–74.CrossRefPubMedCentralPubMed
63.
Isordia-Salas I, Pixley RA, Li F, Sainz I, Sartor RB, Adam A, et al. Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol. 2002;283(1):G180–6.CrossRefPubMed
64.
Hara DB, Leite DFP, Fernandes ES, Passos GF, Guimarães AO, Pesquero JB, et al. The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol. 2008;154(6):1276–86.CrossRefPubMedCentralPubMed
65.
Lu F, Fernandes SM, Davis AE. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2010;298(6):G878–83.
Metadata
Title
Contact pathway of coagulation and inflammation
Author
Yi Wu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2015
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-015-0048-y

Other articles of this Issue 1/2015

Thrombosis Journal 1/2015 Go to the issue

Original clinical investigation

Global Thrombosis Test – a possible monitoring system for the effects and safety of dabigatran

Original clinical investigation

Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients

Review

Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?

Review

Assays of different aspects of haemostasis – what do they measure?

Original clinical investigation

A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

Original clinical investigation

The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits